IAPP and Alzheimer disease: Thus, although longer half-life, stability and bioavailability are desirable attributes in the search for amylin based peptides as therapeutic agents for diabetes and other systemic conditions, in the case of AD, the ability of such peptides to cross the blood brain barrier is an important consideration for their therapeutic potential in the CNS.